Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1988 1
1989 1
1995 1
1998 2
1999 1
2001 1
2002 1
2004 3
2005 2
2006 2
2007 1
2008 2
2009 4
2010 6
2011 6
2012 8
2013 7
2014 4
2015 5
2016 7
2017 9
2018 12
2019 7
2020 13
2021 13
2022 7
2023 3
2024 10
2025 10
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
Parkinson's disease.
Bloem BR, Okun MS, Klein C. Bloem BR, et al. Lancet. 2021 Jun 12;397(10291):2284-2303. doi: 10.1016/S0140-6736(21)00218-X. Epub 2021 Apr 10. Lancet. 2021. PMID: 33848468 Review.
Diagnosis and Treatment of Parkinson Disease: A Review.
Armstrong MJ, Okun MS. Armstrong MJ, et al. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. JAMA. 2020. PMID: 32044947 Review.
IMPORTANCE: Parkinson disease is the most common form of parkinsonism, a group of neurological disorders with Parkinson disease-like movement problems such as rigidity, slowness, and tremor. ...Nonmotor symptoms require nondopaminergic approaches (eg, selective serotonin r …
IMPORTANCE: Parkinson disease is the most common form of parkinsonism, a group of neurological disorders with Parkinson disease-like …
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS; HERCULES Trial Group. Fox RJ, et al. N Engl J Med. 2025 May 15;392(19):1883-1892. doi: 10.1056/NEJMoa2415988. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202696 Free article. Clinical Trial.
BACKGROUND: Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclerosis have limited effects on disability accrual unrelated to rela …
BACKGROUND: Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called …
Parkinson's disease as a somato-cognitive action network disorder.
Ren J, Zhang W, Dahmani L, Gordon EM, Li S, Zhou Y, Long Y, Huang J, Zhu Y, Guo N, Jiang C, Zhang F, Bai Y, Wei W, Wu Y, Bush A, Vissani M, Wei L, Oehrn CR, Morrison MA, Zhu Y, Zhang C, Hu Q, Yin Y, Cui W, Fu X, Zhang P, Wang W, Ji GJ, He J, Wang K, Fan D, Wang Z, Kimberley T, Little S, Starr PA, Richardson RM, Li L, Wang M, Wang D, Dosenbach NUF, Liu H. Ren J, et al. Nature. 2026 Mar;651(8107):1030-1038. doi: 10.1038/s41586-025-10059-1. Epub 2026 Feb 4. Nature. 2026. PMID: 41639440 Free PMC article.
Parkinson's disease (PD) is an incurable neurological disorder that often begins insidiously with sleep disturbances and somatic symptoms, progressing to whole-body motor and cognitive symptoms(1-5). ...To investigate the role of the SCAN in PD pathophysiology and treatmen …
Parkinson's disease (PD) is an incurable neurological disorder that often begins insidiously with sleep disturbances and somatic symp …
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
BACKGROUND: Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis. We aimed to determine t …
BACKGROUND: Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase, an enzyme expressed in …
Trial of Deferiprone in Parkinson's Disease.
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Růžička E, Dušek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garçon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Devos D, et al. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254. N Engl J Med. 2022. PMID: 36449420 Clinical Trial.
Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. ...
Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content …
Neuroprotective effects of intranasal extracellular vesicles from human platelet concentrates supernatants in traumatic brain injury and Parkinson's disease models.
Delila L, Nebie O, Le NTN, Timmerman K, Lee DY, Wu YW, Chou ML, Buée L, Chou SY, Blum D, Devos D, Burnouf T. Delila L, et al. J Biomed Sci. 2024 Sep 5;31(1):87. doi: 10.1186/s12929-024-01072-z. J Biomed Sci. 2024. PMID: 39237980 Free PMC article.
BACKGROUND: The burgeoning field of regenerative medicine has significantly advanced with recent findings on biotherapies using human platelet lysates (HPLs), derived from clinical-grade platelet concentrates (PCs), for treating brain disorders. These developments have ope …
BACKGROUND: The burgeoning field of regenerative medicine has significantly advanced with recent findings on biotherapies using human platel …
SLITRK2 variants associated with neurodevelopmental disorders impair excitatory synaptic function and cognition in mice.
El Chehadeh S, Han KA, Kim D, Jang G, Bakhtiari S, Lim D, Kim HY, Kim J, Kim H, Wynn J, Chung WK, Vitiello G, Cutcutache I, Page M, Gecz J, Harper K, Han AR, Kim HM, Wessels M, Bayat A, Jaén AF, Selicorni A, Maitz S, de Brouwer APM, Silfhout AV, Armstrong M, Symonds J, Küry S, Isidor B, Cogné B, Nizon M, Feger C, Muller J, Torti E, Grange DK, Willems M, Kruer MC, Ko J, Piton A, Um JW. El Chehadeh S, et al. Nat Commun. 2022 Jul 15;13(1):4112. doi: 10.1038/s41467-022-31566-z. Nat Commun. 2022. PMID: 35840571 Free PMC article.
Strikingly, these variations abolished the ability of SLITRK2 wild-type to reduce the levels of the receptor tyrosine kinase TrkB in neurons. Moreover, Slitrk2 conditional knockout mice exhibited impaired long-term memory and abnormal gait, recapitulating a subset of clini …
Strikingly, these variations abolished the ability of SLITRK2 wild-type to reduce the levels of the receptor tyrosine kinase TrkB in …
The role of L-DOPA in neurological and neurodegenerative complications: a review.
Kulkarni SR, Thokchom B, Abbigeri MB, Bhavi SM, Singh SR, Metri N, Yarajarla RB. Kulkarni SR, et al. Mol Cell Biochem. 2025 Oct;480(10):5221-5242. doi: 10.1007/s11010-025-05324-w. Epub 2025 Jun 9. Mol Cell Biochem. 2025. PMID: 40488810 Review.
Its ability to cross the blood-brain barrier (BBB) makes it a crucial therapeutic agent for restoring dopaminergic neurotransmission, thereby influencing motor function, cognition, and neuroprotection. ...Furthermore, L-DOPA has demonstrated efficacy in neurologi …
Its ability to cross the blood-brain barrier (BBB) makes it a crucial therapeutic agent for restoring dopaminergic neurotransmission, …
Roles of Nutrients in the Brain Development, Cognitive Function, and Mood of Dogs and Cats.
Wu G. Wu G. Adv Exp Med Biol. 2024;1446:177-202. doi: 10.1007/978-3-031-54192-6_8. Adv Exp Med Biol. 2024. PMID: 38625529
The brain is the central commander of all physical activities and the expression of emotions in animals. ...Some amino acids (e.g., arginine, glycine, methionine, serine, taurine, tryptophan, and tyrosine) can help to alleviate behavioral and mood disorders (e.g., d …
The brain is the central commander of all physical activities and the expression of emotions in animals. ...Some amino acids (e.g., a …
133 results